AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Comparative Study of the Efficacy of Biologics vs Usual Treatment on OCS Reduction for Severe Asthma Patients Using Health Insurance Claim Database

Completed

Conditions: Asthma

First Posted Date: 2021-11-29

Last Posted Date: 2023-03-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 2927

Registration Number: NCT05136547

Locations: 🇯🇵
Research Site, Tokyo, Japan

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

Completed

Conditions: Prevention of Infectious Disease Caused by SARS-CoV-2

First Posted Date: 2021-11-26

Last Posted Date: 2024-01-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 467

Registration Number: NCT05135455

Locations: 🇯🇵
Research Site, Tokyo, Japan

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: AZD5055
Drug: Placebo

First Posted Date: 2021-11-26

Last Posted Date: 2024-05-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 63

Registration Number: NCT05134727

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Dapagliflozin Post Marketing Surveillance in HF and CKD

Completed

Conditions: Heart Failure
Chronic Kidney Disease

First Posted Date: 2021-11-26

Last Posted Date: 2025-01-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 815

Registration Number: NCT05134701

Locations: 🇰🇷
Research Site, Uijeongbu-si, Korea, Republic of

EU Secondary Data Post-Authorisation Safety Study of AZD1222

Completed

Conditions: COVID-19, Vaccine Adverse Events of Special Interest

Interventions: Biological: AZD1222

First Posted Date: 2021-11-19

Last Posted Date: 2025-01-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 5321930

Registration Number: NCT05126992

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Phase 1

Recruiting

Conditions: Breast Cancer
Biliary Tract Carcinoma
Ovarian Cancer
Endometrial Cancer
Squamous Non-Small Cell Lung Cancer

Interventions: Drug: AZD8205 and AZD2936 (Rilvegostomig)
Drug: AZD8205 and AZD5305 (saruparib)
Drug: AZD8205
Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)

First Posted Date: 2021-11-17

Last Posted Date: 2025-05-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 370

Registration Number: NCT05123482

Locations: 🇬🇧
Research Site, London, United Kingdom

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Osimertinib

First Posted Date: 2021-11-15

Last Posted Date: 2025-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 390

Registration Number: NCT05120349

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Neoplasms
HER2-positive Early Breast Cancer
Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Trastuzumab Deruxtecan
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Doxorubicin
Drug: cyclophosphamide

First Posted Date: 2021-11-09

Last Posted Date: 2025-05-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 927

Registration Number: NCT05113251

Locations: 🇹🇭
Research Site, Khon Kaen, Thailand

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment
Hepatic Impairment

Interventions: Drug: Zibotentan

First Posted Date: 2021-11-08

Last Posted Date: 2022-01-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT05112419

Locations: 🇧🇬
Research Site, Sofia, Bulgaria

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD8630
Drug: Placebo

First Posted Date: 2021-11-08

Last Posted Date: 2023-08-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 170

Registration Number: NCT05110976

Locations: 🇬🇧
Research Site, Portsmouth, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy